Synergism of CPT-11 and Apo2L/TRAIL against Two Differentially Sensitive Human Colon Tumor Xenografts
- 20 August 2008
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 74 (3-4) , 188-197
Abstract
Objective: The ability to sustain and grow portions of human tumors as xenografts in SCID mice provides a valuable preclinical opportunity to test the response of human tumors to treatments, both individually and in combination. Using this model, our laboratory has previously demonstrated that the growth of several human adenocarcinomas can be inhibited by Apo2L/TRAIL. Apo2L/TRAIL triggers apoptosis in many types of tumor cells, and when combined with various chemotherapeutic agents results in enhanced inhibition of tumor growth in many xenograft models. Methods: To gain further insight into the antitumor potential of Apo2L/TRAIL in combination with chemotherapy, we compared the responses of 2 human colon adenocarcinomas, both of which were sensitive to CPT-11 while one was sensitive and the other comparatively resistant to Apo2L/TRAIL. Results: In both cases, a greater degree of growth inhibition was achieved when these agents were used in combination. Western blot analysis demonstrated that in the Apo2L/TRAIL-sensitive tumor total cellular expression of Apo2L/TRAIL death receptors (DR4 and DR5) as well as protein expression of the pro-apoptotic molecule BAX were higher and the anti-apoptotic molecule Bcl-2 was lower in comparison to the Apo2L/TRAIL-resistant tumor. Conclusion: These results indicate that both Apo2L/TRAIL-sensitive and -resistant colon tumors will respond to a combination of CPT-11 and Apo2L/TRAIL and predict that this will be useful in the treatment of human colon cancers in a clinical setting.Keywords
This publication has 37 references indexed in Scilit:
- An In vivo Platform for Translational Drug Development in Pancreatic CancerClinical Cancer Research, 2006
- Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve SurvivalCancer Research, 2004
- Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapyCytokine & Growth Factor Reviews, 2003
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2Oncogene, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional featuresOncogene, 1999
- The Receptor for the Cytotoxic Ligand TRAILScience, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995